Compare ARCO & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCO | MPLT |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | Uruguay | United States |
| Employees | N/A | 133 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2011 | N/A |
| Metric | ARCO | MPLT |
|---|---|---|
| Price | $8.16 | $13.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $8.60 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 1.3M | 1.3M |
| Earning Date | 05-20-2026 | 05-28-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.56 | N/A |
| Revenue Next Year | $3.48 | N/A |
| P/E Ratio | $7.26 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.54 | $9.10 |
| 52 Week High | $9.75 | $40.43 |
| Indicator | ARCO | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 44.78 | 28.78 |
| Support Level | $8.02 | N/A |
| Resistance Level | $8.54 | $20.73 |
| Average True Range (ATR) | 0.20 | 2.62 |
| MACD | 0.00 | -2.97 |
| Stochastic Oscillator | 15.53 | 15.49 |
Arcos Dorados Holdings Inc operates McDonald's branded restaurants in various countries and territories in Latin America and the Caribbean. The Company manages its business as distinct geographic segments and its operations are divided into three geographic divisions, as follows: Brazil, the North Latin American division, or NOLAD, which is comprised of Costa Rica, Mexico, Panama, Puerto Rico, Martinique, Guadeloupe, French Guiana and the U.S. Virgin Islands of St. Croix and St. Thomas and the South Latin American division, or SLAD, which is comprised of Argentina, Chile, Ecuador, Peru, Uruguay, Colombia, Venezuela, Trinidad and Tobago, Aruba and Curacao. Its menu includes hamburgers, McNuggets, salad, sandwiches, French fries, and others. It generates maximum revenue from Brazil.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.